| Shelby County Treatment Center | |
|
750 Highway 31 S Alabaster AL 35007-4627 | |
| (205) 216-0200 | |
| (205) 216-0203 |
| Full Name | Shelby County Treatment Center |
|---|---|
| Speciality | Community/Behavioral Health |
| Location | 750 Highway 31 S, Alabaster, Alabama |
| Authorized Official Name and Position | Susan Michelle Staats-sidwell (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 2052160200 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Shelby County Treatment Center 750 Highway 31 S Alabaster AL 35007-4627 Ph: (205) 216-0200 | Shelby County Treatment Center 750 Highway 31 S Alabaster AL 35007-4627 Ph: (205) 216-0200 |
| NPI Number | 1992031371 |
|---|---|
| Provider Enumeration Date | 10/20/2009 |
| Last Update Date | 10/20/2009 |
| Medicare PECOS PAC ID | 1456785393 |
|---|---|
| Medicare Enrollment ID | O20191230002232 |
News Archive
Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
PDL BioPharma, Inc. today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the record date.
In the latest issue of the journal JAMA Psychiatry Bridget F. Grant and colleagues have reported that alcohol use is rising at an alarming rate in the United States. Both the health and cost implications of this are huge. Opioid related deaths have already made headlines and their rise is accompanied by other substance use feel health officials.
Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.
Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992031371 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | (Alabama) | Primary |
News Archive
Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
PDL BioPharma, Inc. today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the record date.
In the latest issue of the journal JAMA Psychiatry Bridget F. Grant and colleagues have reported that alcohol use is rising at an alarming rate in the United States. Both the health and cost implications of this are huge. Opioid related deaths have already made headlines and their rise is accompanied by other substance use feel health officials.
Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.
Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.
› Verified 5 days ago
Shelby Baptist Medical Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8100 Fax: 205-620-7003 | |
Cheryl R. Goyne, M.d. Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 644 2nd St Ne, Suite 101, Alabaster, AL 35007 Phone: 205-358-1848 | |
Shelby Baptist Medical Center Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8100 Fax: 205-620-7003 | |
Bbh Inpatient Neurology Medicine Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-7004 | |
Shaneyfelt Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Warrior Dr, Alabaster, AL 35007 Phone: 295-685-8192 Fax: 205-685-0446 | |
Neurology Neurodiagnostic Lab Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1004 1st St N, Suite330, Alabaster, AL 35007 Phone: 205-664-2967 Fax: 205-664-9689 | |
Alaquest Center For Performance Excellence, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 213 Wixford Way, Alabaster, AL 35007 Phone: 205-370-8876 |